)
Arcturus Therapeutics (ARCT) investor relations material
Arcturus Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.2027 catalysts and plans
Two mRNA programs have data catalysts in 2027: CF full phase II cohort 4 data in Q2; ARCT-2601 OTC deficiency top-line data in H2.
CF cohort 4 enrollment is continuing through year-end 2026; full data are targeted for Q2 2027, with top-line data expected in between and shared alongside the phase III decision.
If the CF program advances to phase III, Thermo Fisher is expected to contribute up to $40 million; preparation for the trial began in July 2026.
ARCT-2601 clinical trial startup is anticipated in early 2027; initial data from the reformulated candidate are expected in H2 2027.
LUNAR platform and pipeline
LUNAR is the lipid nanoparticle delivery technology; LUNAR 1.0 has established safety, tolerability and efficacy in an approved COVID vaccine across 30+ countries and in an OTC deficiency program.
LUNAR 2.0 showed 38 times better performance than LUNAR 1.0 in primates; the formulation is being applied to OTC deficiency with a focus on less frequent dosing and greater convenience.
The reformulated OTC candidate may enable monthly, lower-dose administration at home instead of clinic dosing every two weeks; this is a proposed goal, subject to clinical results.
PKU has been added to the pipeline, with an IND targeted for H2 2027; LUNAR 2.0 is presented as enabling liver targets that previously required impractical dosing frequency.
Cystic fibrosis program
The inhaled mRNA therapy aims to produce new CFTR protein in lung cells, addressing Class I patients who lack a transporter; about 15% of the CF population do not benefit from modulators, with roughly half of that group Class I.
Earlier dose-ranging tested 5, 10 and 15 mg once daily for about four weeks; CT scans at 10 mg showed improvements in mucus plugging and airway obstruction.
The ongoing 12-week study uses 10 mg once daily, enrolling up to 20 patients in the U.S., Turkey and Israel; measures include spirometry, lung clearance index, quality-of-life assessments and high-resolution CT.
Eligibility was narrowed to 45%–85% predicted lung function, and screening-to-baseline reproducibility criteria were tightened to reduce measurement variability.
Phase III go/no-go will consider the totality of lung-function, imaging and quality-of-life data; stability or improvement versus expected decline would be viewed positively.
- LUNAR 2.0 advances mRNA programs alongside promising CF, OTC, and vaccine data.ARCT
Corporate presentation - Q3 net loss narrowed as LUNAR 2.0 advanced and 2027 clinical milestones approached.ARCT
Q3 2026 - ARCT-810 shows strong safety and efficacy; LUNAR 2.0 enables potent, convenient dosing and pipeline growth.ARCT
Status update - Upcoming phase II data and a pivotal CF decision mark major milestones for the mRNA pipeline.ARCT
H.C. Wainwright 28th Annual Global Investment Conference - Key clinical milestones for liver and lung mRNA therapies expected in the next 6–12 months.ARCT
12th Annual Cantor Fitzgerald Global Healthcare Conference - OTC phase II data and CF phase III decision expected soon, with major funding and tech advances.ARCT
Citigroup’s Biopharma Back to School Summit 2026 - Advancing mRNA therapies for CF and OTC with phase III plans, strong funding, and key partnerships.ARCT
Canaccord Genuity's 46th Annual Growth Conference - Advanced rare disease pipeline, regained vaccine rights, and secured Thermo Fisher partnership.ARCT
Q2 2026 - ARCT-810 delivers strong biomarker and safety results, with key data to be presented June 30, 2025.ARCT
Status Update
Next Arcturus Therapeutics earnings date
Next Arcturus Therapeutics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)